{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/incontinence-urinary-in-women/prescribing-information/intravaginal-oestrogen/","result":{"pageContext":{"chapter":{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen","depth":2,"htmlHeader":"<!-- begin field da73d8d8-821b-43e3-9fd5-6d56bbdf8698 --><h2>Intravaginal oestrogen</h2><!-- end field da73d8d8-821b-43e3-9fd5-6d56bbdf8698 -->","summary":"","htmlStringContent":"<!-- begin item baaa34b6-bebb-471e-993d-7073429fba0d --><!-- end item baaa34b6-bebb-471e-993d-7073429fba0d -->","topic":{"id":"c16535c5-1fa2-5d4a-a89f-9863872fca0e","topicId":"9e411d60-4060-4d95-8511-0998688cea47","topicName":"Incontinence - urinary, in women","slug":"incontinence-urinary-in-women","lastRevised":"Last revised in October 2019","chapters":[{"id":"592d340e-2c89-5e8e-9781-8398ef51af2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"93b3be44-57e0-59a2-b936-4b447f0b2961","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c15069c4-b8dd-5092-9861-e20a636b9367","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3dc5fefe-1cf0-54d7-92d3-e1c0c60c6fb9","slug":"changes","fullItemName":"Changes"},{"id":"fb9741e6-b4f0-5ec2-ada2-a14af327feed","slug":"update","fullItemName":"Update"}]},{"id":"1ae974b5-487a-5fdf-88b5-6d9ed1e83525","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"399a4681-e92c-5e84-a738-fded957e135f","slug":"goals","fullItemName":"Goals"},{"id":"6507910a-37cb-51a9-8d3d-b69725293a87","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9cd9dcb7-4d7b-5d3b-aa75-6fb40bf5928b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f79e3765-8adb-5e3f-b68f-48aa4ddeb34b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e1ab1bca-96c7-5187-894e-1e1fe32f92d6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"97c63b91-f53e-5694-b807-0899dd34d53a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0c2e43fc-1afb-59f4-8819-0ff5edc09eeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3ab1ad04-1d9d-52bc-b4c9-ad0787598df3","slug":"definition","fullItemName":"Definition"},{"id":"a9c53f9f-2962-5eb2-8cae-91fc90a5a1f4","slug":"causes-contributing-factors","fullItemName":"Causes and contributing factors"},{"id":"4bbda54d-1a4f-591c-8463-082fcdf61d7c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e79a0901-9992-5f45-8cf5-c15ce06b5deb","slug":"complications","fullItemName":"Complications"},{"id":"b70db9b0-ddc3-5b42-888e-7171189f4ee5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a84e9562-3c9c-5c5e-8832-06e65a89aa2f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"49f48003-2f49-51d5-acfe-7ba0fcff8fae","slug":"assessment-overview","fullItemName":"Assessment overview"},{"id":"060afa31-1619-5a1a-a7e5-bcb583129aca","slug":"assessing-the-type-of-urinary-incontinence","fullItemName":"Assessing the type of urinary incontinence"},{"id":"9897aa86-8c09-5550-8496-da8cb12787bf","slug":"assessing-for-underlying-causes-contributing-factors","fullItemName":"Assessing for underlying causes and contributing factors"},{"id":"49079af0-34b2-5cab-9135-40f57ee1eea4","slug":"assessing-for-complications","fullItemName":"Assessing for complications"},{"id":"c9c5f464-0433-5027-a22c-8d2b8fb239bd","slug":"assessing-the-severity-of-urinary-incontinence","fullItemName":"Assessing the severity of urinary incontinence"}]},{"id":"a7454b90-f574-597a-b3ce-8f0b3967e058","fullItemName":"Management","slug":"management","subChapters":[{"id":"26043de5-bad9-57d7-abad-98942e3ed62c","slug":"managing-stress-incontinence","fullItemName":"Scenario: Managing stress incontinence"},{"id":"280a972f-ec97-53b4-ab56-b67df1df40d3","slug":"managing-urgency-incontinence","fullItemName":"Scenario: Managing urgency incontinence"},{"id":"dff61990-c7a9-5600-b15a-e9098f480b65","slug":"managing-mixed-urinary-incontinence","fullItemName":"Scenario: Managing mixed urinary incontinence"},{"id":"4e21298e-b75d-5104-9b4b-a9817cb8d9b6","slug":"managing-overflow-urinary-incontinence","fullItemName":"Scenario: Managing overflow urinary incontinence"},{"id":"d5ace44e-cc5a-5618-bb48-24058af84ec8","slug":"managing-a-urogenital-fistula","fullItemName":"Scenario: Managing a urogenital fistula"}]},{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin"},{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen"},{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron"}]},{"id":"3ef95f2d-4da4-5002-9243-64779078fc11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bdb709b8-1321-594d-b446-51244a4b8f41","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ce87fd7-7343-5da1-b9a5-0035a5703c2c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3fe3b863-a1f0-5938-9f0d-bb718d670d28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"947b96f3-7dc6-5136-96f6-431519b4646a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"16662eed-08e1-5333-85c0-65d2e4722f09","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9c5908f0-10fa-5d1c-8762-8a682a1ee2c8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"532bc548-9f39-5742-9a38-cb92893a8407","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"cf62e11d-03e0-5622-835d-6298ec6f93d6","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 7bf01994-9a0c-43af-a2a2-7ec9f1407455 --><h3>Who should not receive intravaginal oestrogens?</h3><!-- end field 7bf01994-9a0c-43af-a2a2-7ec9f1407455 -->","summary":"","htmlStringContent":"<!-- begin item 56178dd5-d9a7-446f-a956-82c971bc3b19 --><!-- begin field 78e6ae16-9836-487d-a894-3a74a971d39c --><ul><li>The manufacturers of topical oestrogens advise that these preparations are contraindicated in people with:<ul><li>Known, past, or suspected breast cancer.</li><li>Known or suspected oestrogen-dependent malignant tumours (such as endometrial cancer).</li><li>Undiagnosed genital bleeding.</li><li>Untreated endometrial hyperplasia.</li><li>Previous or current venous thromboembolism (deep venous thrombosis, or pulmonary embolism).</li><li>Active or recent arterial thromboembolic disease (such as angina and myocardial infarction).</li><li>Known thrombophilic disorders (for example protein C, protein S, or antithrombin deficiency).</li><li>Acute liver disease or a history of liver disease (if liver function tests have failed to return to normal).</li><li>Known hypersensitivity to the active substances or to any of the excipients.</li><li>Porphyria.</li></ul></li><li>If use is indicated in these people, consider seeking specialist advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019i</a>]</p><!-- end field 78e6ae16-9836-487d-a894-3a74a971d39c --><!-- end item 56178dd5-d9a7-446f-a956-82c971bc3b19 -->","subChapters":[]},{"id":"ddf3458a-45a5-5695-bddf-e8e1d7dbd792","slug":"preparations-dosage","fullItemName":"Preparations and dosage","depth":3,"htmlHeader":"<!-- begin field 4c787675-b7e5-4f83-afb7-95e8129d9988 --><h3>What dose of intravaginal oestrogen should I prescribe?</h3><!-- end field 4c787675-b7e5-4f83-afb7-95e8129d9988 -->","summary":"","htmlStringContent":"<!-- begin item ea4c3109-6fda-4759-8098-685eba8d38ec --><!-- begin field 1de59b4b-d5d5-4bcb-a619-7a052c156425 --><ul><li><strong>Topical oestrogens should be used in the lowest effective amount to minimize systemic absorption.</strong><ul><li>Review at least annually to re-assess the need for continued treatment and to monitor for symptoms of endometrial hyperplasia or carcinoma in women with a uterus.</li><li>For the treatment of atrophic vaginitis in post-menopausal women, licensed doses for intravaginal oestrogen preparations are:</li><li>Intravaginal cream:<ul><li>Ovestin<sup>® </sup>(1 mg estriol in 1 gram cream) — insert one applicatorful daily for a maximum of 4 weeks, reducing to one applicatorful twice a week. </li></ul></li><li>Vaginal gel:<ul><li>Blissel<sup>®</sup> (50 micrograms estriol in 1 gram vaginal gel) — insert one applicator dose daily for 3 weeks, reducing to one applicator dose twice a week. Reassess after 12 weeks. </li></ul></li><li>Vaginal tablets:<ul><li>Vagifem<sup>® </sup>vaginal tablets (estradiol 10 micrograms)— insert one vaginal tablet daily for 2 weeks then reduce to one vaginal tablet twice a week.</li></ul></li><li>Vaginal pessary:<ul><li>Imvaggis<sup>® </sup>vaginal pessary (contains 0.03 mg estriol) — insert one vaginal pessary daily for the first 3 weeks, reducing to one vaginal pessary twice a week.</li></ul></li><li>Vaginal ring:<ul><li>Estring<sup>® </sup>(releasing approximately 7.5 micrograms of estradiol over 24 hours) — insert the ring into the upper third of the vagina. The ring is then worn continuously for 3 months before replacing with a new ring. Maximum duration of continuous treatment is 2 years.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI Medicines Compendium, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 1de59b4b-d5d5-4bcb-a619-7a052c156425 --><!-- end item ea4c3109-6fda-4759-8098-685eba8d38ec -->","subChapters":[]},{"id":"68ee4f99-f299-505c-9157-17bd6fe72618","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fda20358-42f8-4ba5-8e13-16115d2bd362 --><h3>What adverse effects of intravaginal oestrogens should I be aware of?</h3><!-- end field fda20358-42f8-4ba5-8e13-16115d2bd362 -->","summary":"","htmlStringContent":"<!-- begin item 3c12d131-c21d-4ade-b6f0-f02c2d9436da --><!-- begin field adf213b0-93fb-4823-a8a7-30fa16617cc0 --><ul><li>The British National Formulary advises that the endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain.<ul><li>Consequently, treatment should be interrupted at least annually to re-assess the need for continued treatment. If bleeding or spotting appears at any time during treatment, the reason should be investigated. Investigations may include endometrial biopsy to exclude endometrial malignancy.</li></ul></li><li>Other adverse effects reported by the manufacturers of intravaginal oestrogens include vulvovaginal discomfort, headache, abdominal pain, nausea and vomiting, and oestrogen-related adverse events (for example breast pain, postmenopausal bleeding). </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI Medicines Compendium, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field adf213b0-93fb-4823-a8a7-30fa16617cc0 --><!-- end item 3c12d131-c21d-4ade-b6f0-f02c2d9436da -->","subChapters":[]},{"id":"c975bad3-3ce8-534f-ae35-58856e0f587a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1c494084-379d-4d38-9f77-046899c427e3 --><h3>What are the key drug interactions with intravaginal oestrogens?</h3><!-- end field 1c494084-379d-4d38-9f77-046899c427e3 -->","summary":"","htmlStringContent":"<!-- begin item db65ebe5-da02-4fac-a4bd-03c3542efc34 --><!-- begin field ae8a7ea6-2d5c-4d00-bf80-981abb11a19c --><ul><li>Manufacturers of some intravaginal oestrogen preparations advise that due to vaginal administration and minimal systemic absorption, clinically relevant drug interactions are unlikely, but interactions with other locally applied vaginal treatments should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019i</a>]. </li></ul><!-- end field ae8a7ea6-2d5c-4d00-bf80-981abb11a19c --><!-- end item db65ebe5-da02-4fac-a4bd-03c3542efc34 -->","subChapters":[]},{"id":"2ed279b7-843d-5c87-b026-e9e4c7d83ac8","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 66ebceb2-0fd3-4c47-8f1f-3b19f9e71747 --><h3>What advice should I give to someone prescribed intravaginal oestrogen?</h3><!-- end field 66ebceb2-0fd3-4c47-8f1f-3b19f9e71747 -->","summary":"","htmlStringContent":"<!-- begin item 47bfa18b-b0e7-4f21-ac0e-9e98fa5f97fa --><!-- begin field b6e480d7-432d-4715-9a5f-16c29997ad50 --><ul><li><strong>Advise the woman that:</strong><ul><li>Topical oestrogens should be used in the lowest effective dose to minimize systemic absorption.</li><li>Medical advice should be sought if she experiences breakthrough bleeding or spotting at any time during treatment. </li></ul></li><li>Warn the woman that certain intravaginal oestrogen preparations can damage contraceptive condoms and diaphragms. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI Medicines Compendium, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field b6e480d7-432d-4715-9a5f-16c29997ad50 --><!-- end item 47bfa18b-b0e7-4f21-ac0e-9e98fa5f97fa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}